Medicine

IMU-856 Shows Promise in Celiac Disease: Histologic Protection and Nutrient Absorption Key to Advancing Trials

February 1, 2025 - By 

Daniel Vitt, CEO, Immunic Therapeutics, discusses promising results from the Phase Ib trial of IMU-856 in celiac disease.

Related Posts

FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk

February 19, 2025

Navigating Distrust: Pharma in the Age of Social Media

February 19, 2025

Pharmaceutical Executive: February 2025 Issue (PDF)

February 18, 2025

Leave a Reply

Your email address will not be published. Required fields are marked *